The “psychedelic drug” label appears to define a clear-cut category. However, there are lesser-known research chemicals that depict more diffuse boundaries in this classification.
Researchers will examine whether MDMA can offset some of the negative side effects of LSD in a therapeutic setting.
Brain scans show that psilocybin modulates claustrum connectivity in brain networks.
The new REBUS model helps explain the subjective and neurochemical effects of psychedelics on the brain.
The catalog of compounds for use in psychedelic drug research continues to grow.
The researchers hope these compounds “will expand the universe of options for improving mental health.”
Surprisingly, 4-HO-TMT has binding affinity similar to psilocin at 5-HT2A.
The primary active compound in this plant is more potent than LSD.
This structural analog of DMT is an understudied compound presenting new options for psychedelic drug development.
Using psychedelics to treat chronic pain is understudied yet full of potential.